Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant gemcitabine + capecitabine vs gemcitabine + cisplatin with regional hyperthermia in resected pancreatic cancer
2008-004802-14Phase 3Terminated
- Sponsor
- LMU Klinikum
- Start
- Apr 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing Gemcitabine + Capecitabine with Gemcitabine + Cisplatin with regional hyperthermia (2 arms). Primary endpoint: Disease-free survival. Started Apr 2009; status: terminated.
02
Drugs
gemcitabinecapecitabinecisplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2008-004802-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004802-14.